ArticleBlood2014
Platelets are required for enhanced activation of the endothelium and fibrinogen in a mouse thrombosis model of APS.
Article in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 2 syntheses or guidelines pooled it, 116 citations in OpenAlex.
- Proteins upregulated in thrombotic antiphospholipid syndrome linked to platelet function in contrast with non-antiphospholipid-related thrombosis: insights from two systematic reviews.Lupus science & medicine · 2025Pooled it
- A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations.Blood advances · 2021Pooled it
- Mechanisms sensitive to different drugs mediate a proadhesive and pro-thrombotic platelet phenotype in antiphospholipid syndrome.Haematologica · 2026Article
- Animal models of antiphospholipid syndrome.Frontiers in immunology · 2026Review
- Role of monocytes in the pathogenesis of antiphospholipid syndrome and potential therapeutic targets (Review).Molecular medicine reports · 2025Review
- Endo-chip laser-induced thrombus formation: a vessel-on-chip model for in vitro testing of antithrombotic agents.Blood vessels, thrombosis & hemostasis · 2025Article
- Pediatric antiphospholipid syndrome: expanding our understanding of antiphospholipid syndrome in children.Current opinion in rheumatology · 2025Review
- Understanding the structure of βBlood vessels, thrombosis & hemostasis · 2025Review
- Antigenic assessment for the β2-glycoprotein I/Platelet factor 4 complex in thrombotic patients with antiphospholipid syndrome.Frontiers in immunology · 2025Article
- Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome.Frontiers in immunology · 2025Review
- The well-defined antiphospholipid syndrome induced by COVID-19: a rare case report and review of the literature.Thrombosis journal · 2024Review
- Antiphospholipid Antibodies Modify the Prognostic Value of Baseline Platelet Count for Clinical Outcomes After Ischemic Stroke.Journal of the American Heart Association · 2024Article
- Platelets and Thrombotic Antiphospholipid Syndrome.Journal of clinical medicine · 2024Review
- Tacrolimus shows adequate efficacy in patients with antiphospholipid antibodies associated thrombocytopenia: a retrospective cohort study.Clinical and experimental medicine · 2023Article
- Endothelial Progenitor Cells in Autoimmune Disorders.Stem cell reviews and reports · 2023Review
- An update on the biologics for the treatment of antiphospholipid syndrome.Frontiers in immunology · 2023Review
- Antiphospholipid antibodies in patients with stroke during COVID-19: A role in the signaling pathway leading to platelet activation.Frontiers in immunology · 2023Article
- Anticoagulant Therapy in Patients with Antiphospholipid Syndrome.Journal of clinical medicine · 2022Review
- COVID-19 and antiphospholipid antibodies.Best practice & research. Clinical haematology · 2022Review
- Review
Corrections and comments
- Commented on by
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
Antiphospholipid syndrome (APS) is defined by thrombosis, fetal loss, and the presence of antiphospholipid antibodies, including anti-β2-glycoprotein-1 autoantibodies (anti-β2GP1) that have a direct role in the pathogenesis of thrombosis in vivo. The cellular targets of the anti-β2GP1 autoantibody/β2GP1 complex in vivo were studied using a laser-induced thrombosis model of APS in a live mouse and human anti-β2GP1 autoantibodies affinity-purified from APS patients. Cell binding of fluorescently labeled β2GP1 and anti-β2GP1 autoantibodies revealed their colocalization on the platelet thrombus but not the endothelium. Anti-β2GP1 autoantibodies enhanced platelet activation, monitored by calcium mobilization, and endothelial activation, monitored by intercellular adhesion molecule-1 expression. When eptifibatide was infused to block platelet thrombus formation, enhanced fibrin generation and endothelial cell activation were eliminated. Thus, the anti-β2GP1 autoantibody/β2GP1 complex binds to the thrombus, enhancing platelet activation, and platelet secretion leads to enhanced endothelium activation and fibrin generation. These results lead to a paradigm shift away from the concept that binding of the anti-β2GP1 autoantibody/β2GP1 complex activates both endothelial cells and platelets toward one in which activation of platelets in response to anti-β2GP1 autoantibody/β2GP1 complex binding leads to subsequent enhanced endothelium activation and fibrin generation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.